Recordati SpA - Company Profile
Powered by 
All the data and insights you need on Recordati SpA in one report.
$295
- Save hours of research time and resources with
our up-to-date Recordati SpA Strategy Report
- Understand Recordati SpA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Recordati SpA (Recordati), a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, central nervous system disorders, dermatology, musculoskeletal disorders and analgesia, and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives, and others. It manufactures pharmaceutical chemicals such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries of its operations and through licensees in other places. Recordati is headquartered in Milan, Italy.
Headquarters
Italy
Address
Via Matteo Civitali, 1, Milano, 20148
Website
recordati.com
Telephone
39 02 487871
No of Employees
4,455
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
REC (BIT)
Revenue (2022)
$2.3B
12.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
24.6%
(2022 vs 2021)
Market Cap*
$11.0B
Net Profit Margin (2022)
XYZ
10.9%
(2022 vs 2021)
* As of and is in US$
Recordati SpA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Specialty and Primary Care | Eligard |
| Pharmaceutical Chemicals | Flatoril |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In July, the company entered into an agreement with GSK for the marketing of Avodart (dutasteride) Combodart/Duodart (dutasteride/tamsulosin) in 21 countries. |
| 2022 | Acquisitions/Mergers/Takeovers | In March, the company acquired the UK-based EUSA Pharma for US$848.9 million. |
| 2021 | Acquisitions/Mergers/Takeovers | In April, the company entered into the merger deed relating to the merger by absorption of Rossini Investimenti S.P.A. and Fimei S.P.A. into Recordati S.P.A. |
Competitor Comparison
| Key Parameters | Recordati SpA | UCB SA | Les Laboratoires Servier SAS | Ipsen SA | Zambon Co SpA |
|---|---|---|---|---|---|
| Headquarters | Italy | Belgium | France | France | Italy |
| City | Milano | Anderlecht | Suresnes | Boulogne-Billancourt | Milano |
| State/Province | - | - | Ile-de-France | Bourgogne | Lombardia |
| No. of Employees | 4,455 | 9,083 | 21,400 | 5,072 | 2,720 |
| Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Andrea Recordati | Chairman | Executive Board | 2021 | - |
| Robert Koremans | Director; Chief Executive Officer | Executive Board | 2021 | - |
| Luigi La Corte | Director; Chief Financial Officer | Executive Board | 2019 | - |
| Bibianne Bon | Chief Legal Officer | Senior Management | 2023 | - |
| Guido Guidi | Vice Chairman | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward